Category: Markets
Published: 2026-06-22T22:10:00.000Z
Moderna's investigational flu vaccine candidate (mRNA-1010) received unanimous FDA advisory panel approval, with a regulatory decision expected by August 5. The stock has surged over 100% this year as the company reaches a key transition point with multiple product launches planned for 2027-2028. However, the analyst suggests waiting for a post-approval dip to buy, as much of the good news may already be priced in.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.